Phase 3b trial shows long-acting injectable therapy outperforms daily oral regimens for patients with detectable HIV-1 and adherence challenges.
Phase 3 PROPEL 3 trial results show daily oral infigratinib significantly improved annualized height velocity and height Z-scores compared with placebo in children with achondroplasia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results